Potential health and economic impacts of dexamethasone treatment for patients with COVID-19

Dexamethasone has been shown to have survival benefits for critically ill patients hospitalised with COVID-19 in the UK. Here, the authors estimated the number of lives that could be saved through a UK and global roll out of the drug and demonstrate that it is a cost-effective option.

Guardado en:

Detalles Bibliográficos
Autores principales:	Ricardo Águas, Adam Mahdi, Rima Shretta, Peter Horby, Martin Landray, Lisa White, the CoMo Consortium
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/19242e659b344e0389e9a25b8446b114
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:19242e659b344e0389e9a25b8446b114
record_format	dspace
spelling	oai:doaj.org-article:19242e659b344e0389e9a25b8446b1142021-12-02T14:26:51ZPotential health and economic impacts of dexamethasone treatment for patients with COVID-1910.1038/s41467-021-21134-22041-1723https://doaj.org/article/19242e659b344e0389e9a25b8446b1142021-02-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-21134-2https://doaj.org/toc/2041-1723Dexamethasone has been shown to have survival benefits for critically ill patients hospitalised with COVID-19 in the UK. Here, the authors estimated the number of lives that could be saved through a UK and global roll out of the drug and demonstrate that it is a cost-effective option.Ricardo ÁguasAdam MahdiRima ShrettaPeter HorbyMartin LandrayLisa Whitethe CoMo ConsortiumNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Ricardo Águas Adam Mahdi Rima Shretta Peter Horby Martin Landray Lisa White the CoMo Consortium Potential health and economic impacts of dexamethasone treatment for patients with COVID-19
description	Dexamethasone has been shown to have survival benefits for critically ill patients hospitalised with COVID-19 in the UK. Here, the authors estimated the number of lives that could be saved through a UK and global roll out of the drug and demonstrate that it is a cost-effective option.
format	article
author	Ricardo Águas Adam Mahdi Rima Shretta Peter Horby Martin Landray Lisa White the CoMo Consortium
author_facet	Ricardo Águas Adam Mahdi Rima Shretta Peter Horby Martin Landray Lisa White the CoMo Consortium
author_sort	Ricardo Águas
title	Potential health and economic impacts of dexamethasone treatment for patients with COVID-19
title_short	Potential health and economic impacts of dexamethasone treatment for patients with COVID-19
title_full	Potential health and economic impacts of dexamethasone treatment for patients with COVID-19
title_fullStr	Potential health and economic impacts of dexamethasone treatment for patients with COVID-19
title_full_unstemmed	Potential health and economic impacts of dexamethasone treatment for patients with COVID-19
title_sort	potential health and economic impacts of dexamethasone treatment for patients with covid-19
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/19242e659b344e0389e9a25b8446b114
work_keys_str_mv	AT ricardoaguas potentialhealthandeconomicimpactsofdexamethasonetreatmentforpatientswithcovid19 AT adammahdi potentialhealthandeconomicimpactsofdexamethasonetreatmentforpatientswithcovid19 AT rimashretta potentialhealthandeconomicimpactsofdexamethasonetreatmentforpatientswithcovid19 AT peterhorby potentialhealthandeconomicimpactsofdexamethasonetreatmentforpatientswithcovid19 AT martinlandray potentialhealthandeconomicimpactsofdexamethasonetreatmentforpatientswithcovid19 AT lisawhite potentialhealthandeconomicimpactsofdexamethasonetreatmentforpatientswithcovid19 AT thecomoconsortium potentialhealthandeconomicimpactsofdexamethasonetreatmentforpatientswithcovid19
_version_	1718391294440505344

Potential health and economic impacts of dexamethasone treatment for patients with COVID-19

Ejemplares similares